Trials / Completed
CompletedNCT03571620
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
A Multicenter, Randomized, Phase 2, Double-blind, Vehicle-controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of Q301 Cream in Adolescents and Adults With Mild to Moderate Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Qurient Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Q301 Cream | 1.0% or 1.4% Q301 Cream |
| DRUG | Vehicle | Vehicle Control |
Timeline
- Start date
- 2018-06-21
- Primary completion
- 2019-11-30
- Completion
- 2020-04-21
- First posted
- 2018-06-27
- Last updated
- 2020-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03571620. Inclusion in this directory is not an endorsement.